Co-working firm Venture X gets ready for its grand opening in RTP Date Published: February 10, 2020 RALEIGH — There’s a new co-working space in the City of Oaks, and it’s called Venture X. The Florida-based firm…
Duke spinout Polarean exceeds expectations with lung-imaging trial, seeks meeting with FDA Date Published: February 7, 2020 A successful Phase 3 trial of Polarean Imaging’s drug-device combination for lung imaging has the Research Triangle Park company poised…
NC State, biopharma company developing gene therapy for asthma Date Published: February 6, 2020 NEW YORK, N.Y. — Biopharmaceutical company Hoth Therapeutics has tapped NC State to collaborate and carry out a preclinical study…
NC Biotech CEO Doug Edgeton: ‘We will lead science behind curative gene, cell therapies” Date Published: January 31, 2020 RESEARCH TRIANGLE PARK — For the better part of four decades, North Carolina has steadily committed resources to developing biotechnologies…
Insurtech startup Policygenius, with HQ2 in Durham, raises $100M Date Published: January 30, 2020 NEW YORK — Policygenius, an insurtech startup with its second headquarters based in Durham, announced today $100 million in Series…
bluebird bio launches gene therapy for severe blood disorder in Germany Date Published: January 29, 2020 DURHAM — bluebird bio, a gene therapy company with operations in Durham, has launched for the first time its treatment…
Here’s how UNC is helping make RTP region a startup boom region Date Published: January 16, 2020 Increasingly, the Research Triangle Park region and North Carolina is becoming a hotbed for startups and entrepreneurs, fueled in part…
RTP agtech accelerator offers $100,000 prize to a startup Date Published: January 15, 2020 RESEARCH TRIANGLE PARK – Alexandria Real Estate, which operates the Alexandria LaunchLabs accelerator in RTP, is offering a $100,000 prize…
A world first: Triangle’s Locus Biosciences to launch gene editing trial involving therapy ‘cocktail’ Date Published: January 10, 2020 Morrisville-based Locus Biosciences, a developer of precision antibacterial therapies, will conduct the world’s first clinical trial of a recombinant bacteriophage…